Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Renée Galá Biography and Net Worth

CFO of Jazz Pharmaceuticals

Ms. Galá brings more than 25 years of experience across finance, strategy, leadership development and corporate development. Her role as CFO gives her oversight of all Jazz’s finance operations, including strategy, planning & analysis, investor relations, corporate development, and transformation functions. Ms. Galá’s prior experience as CFO of both another public company and a private company makes her especially skilled at the role. Ms. Galá became Jazz’s CFO in March 2020, and she is a passionate proponent of improving diversity within the healthcare industry.

What is Renée D. Galá's net worth?: The estimated net worth of Renée D. Galá is at least $3.94 million as of May 18th, 2023. Ms. Galá owns 35,978 shares of Jazz Pharmaceuticals stock worth more than $3,938,152 as of April 28th. This net worth estimate does not reflect any other investments that Ms. Galá may own. Learn More about Renée D. Galá's net worth.
How do I contact Renée D. Galá?: The corporate mailing address for Ms. Galá and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Renée D. Galá's contact information.
Has Renée D. Galá been buying or selling shares of Jazz Pharmaceuticals?: Renée D. Galá has not been actively trading shares of Jazz Pharmaceuticals during the last quarter. Most recently, Renee D. Gala sold 6,000 shares of the business's stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $131.75, for a transaction totalling $790,500.00. Following the completion of the sale, the chief financial officer now directly owns 35,978 shares of the company's stock, valued at $4,740,101.50. Learn More on Renée D. Galá's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Robert Iannone (EVP), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 10 times. They sold a total of 13,870 shares worth more than $1,827,470.63. The most recent insider tranaction occured on March, 6th when CAO Patricia Carr sold 1,936 shares worth more than $231,623.04. Insiders at Jazz Pharmaceuticals own 4.4% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 3/6/2024.

Renée D. Galá Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/18/2023	Sell	6,000	$131.75	$790,500.00	35,978
12/21/2022	Sell	2,635	$160.00	$421,600.00	32,558

Renée D. Galá Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $109.46

$106.73

$110.82

50 Day Range

MA: $118.25

$107.10

$132.77

2 Week Range

Now: $109.46

$106.61

$146.70

Volume

480,575 shs

Average Volume

504,507 shs

Market Capitalization

$6.90 billion

P/E Ratio

17.89

Dividend Yield

N/A

Beta

0.59

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad